Skip to main content

Advertisement

SpringerLink
Log in

Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Osteopontin (OPN) is known to be significantly involved in the pathogenesis of rheumatoid arthritis (RA). This study aimed to evaluate if the serum concentration of OPN in patients with RA before and after therapeutic treatments was correlated to disease activity and response to therapy. Blood samples from 40 patients with RA were collected at baseline and six months after starting treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of OPN were measured by ELISA. At baseline, the serum OPN level in RA patients was significantly higher than that of the healthy group. The OPN level at baseline in RA patients with severe disease activity as evaluated by DAS28 was slightly higher than that of those with moderate disease activity. The serum OPN level in RA patients was not significantly correlated with the DAS28 level. The serum OPN level in both responders and non-responders after therapy was significantly decreased regardless of responsiveness to therapy. Also, the OPN level at baseline did not affect the responsiveness to therapeutic treatments. In conclusion, serum OPN level was not correlated with disease activity or responsiveness of RA patients to therapeutic treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429–442

    Article  CAS  PubMed  Google Scholar 

  2. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O (2011) What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7(9):528–536

    Article  CAS  PubMed  Google Scholar 

  3. Zheng W, Li R, Pan H, He D, Xu R, Guo TB, Guo Y, Zhang JZ (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60(7):1957–1965

    Article  CAS  PubMed  Google Scholar 

  4. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J (2005) Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32(3):410–416

    CAS  PubMed  Google Scholar 

  5. Braitch M, Constantinescu CS (2010) The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets 9(4):249–256

    Article  CAS  PubMed  Google Scholar 

  6. Frenzel DF, Weiss JM (2011) Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol 7(1):93–109

    Article  CAS  PubMed  Google Scholar 

  7. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M (2010) Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev 18(3):125–131

    Article  PubMed  Google Scholar 

  8. Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27(11):2302–2309

    Article  CAS  PubMed  Google Scholar 

  9. Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A (2009) Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 36(2):240–245

    Article  CAS  PubMed  Google Scholar 

  10. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6):333–345

    Article  CAS  PubMed  Google Scholar 

  11. Morimoto J, Kon S, Matsui Y, Uede T (2010) Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11(4):494–505

    Article  CAS  PubMed  Google Scholar 

  12. Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F (2009) Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol 36(10):2308–2313

    Article  CAS  PubMed  Google Scholar 

  13. Straburzynska-Lupa A, Nowak A, Romanowski W, Korman P, Pilaczynska-Szczesniak L (2013) A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. J Bone Miner Metab 31(2):169–176

    Article  PubMed  Google Scholar 

  14. Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47(12):1775–1779

    Article  CAS  Google Scholar 

  15. Jacobs JP, Pettit AR, Shinohara ML, Jansson M, Cantor H, Gravallese EM, Mathis D, Benoist C (2004) Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum 50(8):2685–2694

    Article  CAS  PubMed  Google Scholar 

  16. Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, Maeda M, Uede T, Liaw L, Kinoshita N et al (2004) Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 316(3):809–815

    Article  CAS  PubMed  Google Scholar 

  17. Boumans MJ, Houbiers JG, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J et al (2012) Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 71(2):180–185

    Article  CAS  PubMed  Google Scholar 

  18. Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH (2010) Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage 18(1):82–87

    Article  CAS  PubMed  Google Scholar 

  19. Honsawek S, Tanavalee A, Sakdinakiattikoon M, Chayanupatkul M, Yuktanandana P (2009) Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem 42(9):808–812

    Article  CAS  PubMed  Google Scholar 

  20. Naldini A, Leali D, Pucci A, Morena E, Carraro F, Nico B, Ribatti D, Presta M (2006) Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 177(7):4267–4270

    CAS  PubMed  Google Scholar 

  21. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79–87

    Article  CAS  PubMed  Google Scholar 

  22. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G et al (2008) Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149(3):1350–1357

    Article  CAS  PubMed  Google Scholar 

  23. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA et al (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92(9):3719–3727

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011–0009061) and Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).

Disclosures

None.

Author information

Authors and Affiliations

  1. East-West Bone & Joint Research Institute, Kyung Hee University, 149 Sangil-dong, Gangdong-gu, Seoul, 134-727, Republic of Korea

    Hye-In Ji, Myung Chul Yoo & Kyoung Soo Kim

  2. Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital at Gandong, 149 Sangil-dong, Gangdong-gu, Seoul, 134-727, Republic of Korea

    Sang-Hoon Lee, Ran Song & Hyung-In Yang

  3. Division of Rheumatology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Hoegi-dong, Dongdaemun-gu, Seoul, 130-702, Republic of Korea

    Yeon-Ah Lee, Seung-Jae Hong & Somi Kim

  4. Divsion of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 250 Sungsanno, Seodaemoon-gu, Seoul, 120-752, Republic of Korea

    Yong-Beom Park & Soo-Kon Lee

Authors
  1. Hye-In Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang-Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ran Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyung-In Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yeon-Ah Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seung-Jae Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Somi Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong-Beom Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Soo-Kon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Myung Chul Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kyoung Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyoung Soo Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ji, HI., Lee, SH., Song, R. et al. Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis. Clin Rheumatol 33, 397–402 (2014). https://doi.org/10.1007/s10067-013-2375-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-013-2375-3

Keywords

Search

Navigation